Downregulation of TGR5 signaling reduces GLP-1 production, resulting in decreased satiety, increased insulin resistance, and obesity, which are critical factors in the onset and progression of MASLD [70,71,72]. The gene discussed is GPBAR1; the disease is metabolic dysfunction-associated steatotic liver disease.